相关实验视频

Updated: Jan 14, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

单独使用阿司匹林与MASLD中的死亡率和肝脏相关事件的关联:一项多机构为期三年的研究

Chien-Hao Huang^1,2,3, Chun-Li Wang^2,4, Victor Chien-Chia Wu^2,4

¹Division of Hepatology, Department of Gastroenterology and Hepatology, Chang-Gung Memorial Hospital, Linkou Medical Center, Linkou, Taiwan.

Annals of medicine

|October 17, 2025

概括

每天使用阿司匹林在三年内,在代谢功能障碍相关的脂肪性肝病 (MASLD) 患者中,并没有显著降低死亡率或肝脏事件. 然而,趋势表明潜在的长期益处,需要进一步研究MASLD管理.

科学领域:

肝病学肝病学是一种肝病学.
胃肠病学胃肠病学
临床研究临床研究

背景情况:

与代谢功能障碍相关的脂肪性肝病 (MASLD),以前称为NAFLD,是一个日益严重的全球健康问题.
以前的研究表明,阿司匹林可能会降低NAFLD中肝细胞癌 (HCC) 的风险.
阿司匹林对MASLD死亡率和肝脏结果的影响尚未得到充分证实.

研究的目的:

调查每日使用阿司匹林与MASLD患者的死亡率和肝脏相关结果之间的关联.
评估阿司匹林对整体死亡率,肝脏相关事件,肝脏相关死亡率和HCC发病率在一个大型MASLD队列中的影响.

主要方法:

在48722名MASLD患者 (2008-2020年) 进行的回顾性多机构队列研究.
倾向分数匹配 (PSM) 创建了可比的阿司匹林使用者和非使用者队列 (2003名患者).
排除标准确保了专注于MASLD和阿司匹林的孤立作用.

主要成果:

服用阿司匹林 (平均4.59年,每天75-100毫克) 并没有显著地与三年内降低整体死亡率,肝脏事件,肝脏死亡率或HCC有关.
在阿司匹林使用者中观察到与肝脏相关的较低死亡率和HCC发病率的趋势.
在使用阿司匹林时,没有发现严重出血风险的显著增加.

结论:

每日阿司匹林单疗法在三年时间内没有显著改善MASLD患者的死亡率或肝脏结果.
观察到的趋势表明阿司匹林在MASLD中具有潜在的长期益处.
需要进一步研究延长阿司匹林持续时间和用于MASLD管理的组合疗法.

关键词:

与代谢功能障碍相关的脂肪性肝病 (MASLD)所有原因的死亡率.抗血小板治疗是一种抗血小板疗法.肝细胞癌 (HCC) 是一种肝细胞癌.与肝脏相关的死亡率主要出血事件主要出血事件非酒精性脂肪肝疾病 (NAFLD) 是一种非酒精性脂肪肝疾病.

相关概念视频

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Coronary Artery Disease V: Interprofessional Care

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...